Novo Nordisk A/S (NYSE:NVO) Trading Down 0.2% – Time to Sell?

Novo Nordisk A/S (NYSE:NVO)’s stock price dropped 0.2% during trading on Monday . The stock traded as low as $119.60 and last traded at $119.75. Approximately 687,094 shares changed hands during trading, a decline of 84% from the average daily volume of 4,306,368 shares. The stock had previously closed at $120.04.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. BMO Capital Markets cut their target price on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and an average price target of $145.17.

Novo Nordisk A/S Trading Down 0.1 %

The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. The firm has a market capitalization of $537.97 billion, a P/E ratio of 41.29, a price-to-earnings-growth ratio of 1.53 and a beta of 0.42. The firm has a 50 day moving average price of $129.39 and a two-hundred day moving average price of $132.04.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The company had revenue of $9.82 billion for the quarter, compared to analyst estimates of $9.91 billion. On average, equities research analysts expect that Novo Nordisk A/S will post 3.01 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were issued a dividend of $0.5126 per share. The ex-dividend date was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio is 24.83%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. First PREMIER Bank acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at $25,000. 1620 Investment Advisors Inc. bought a new stake in Novo Nordisk A/S in the 2nd quarter valued at $25,000. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S during the second quarter valued at about $25,000. Dixon Mitchell Investment Counsel Inc. acquired a new position in Novo Nordisk A/S during the first quarter worth $26,000. Finally, Orion Capital Management LLC acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at $26,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.